1.
Sudden onset of symptoms, with severity maximal at onset 2.
Cortical or subcortical lesion localization (by symptoms or imaging) to the territory supplied by the major branches of the ACA, MCA or PCA in the absence of proximal vascular stenosis/occlusion 3.
Clinical or radiographic evidence of embolic infarcts to multiple vascular territories (CNS or systemic), or to the grey-white matter junction 4.
In the lenticulostriate or thalamogeniculate territories, lesions greater than 1 cm should raise suspicion of embolism 5.
Cerebellar hemispheric infarction 6.
The identification of a possible embolic source in the heart (e.g. left atrial or ventricular thrombus, atrial myxoma, atrial fibrillation, valvular disease, cardiomyopathy with ejection fraction < 25%, or acute myocardial infarction), aortic arch or great vessels (thrombus or cholesterol, arterial dissection), venous system in association with intracardiac shunt (fat, tumor, air, deep vein thrombus) or systemic circulation (hyhpercoagulability, hyperviscosity. The failure to identify a high risk source of embolism (cryptogenic, up to 40% of all ischemic strokes) does not exclude an embolic mechanism. Other risk factors for stroke have been suggested by large clinical trials or observational data, including calcified posterior mitral annulus, PFO with or without septal aneurysm, left atrial spontaneous echo contrast, valve strands, atrial flutter, cardiomyopathy with ejection fractions > 25%. 7.
Peri-procedure event in setting of known risk of embolism (cardiac or great vessel surgery, angiography or endovascular manipulation)
Phase 1
Additional Diagnostic Testing • If artery-to-artery embolism is suspected, see management algorithm in Large Vessel section.
Prevention of Acute Recurrent Stroke
• Assess risk of re-embolization during course of acute hospitalization and consider anticoagulation with unfractionated heparin, LMW heparin or heparinoids unless contraindictions for anticoagulation exist (e.g., large area of infarction at significant risk of hemorrhagic transformation, infective endocarditis). Avoid heparin bolus unless suspected basilar embolism or at high risk for reembolism or clot propogation.
• Use hirudin or other non-heparin anticoagulants in patients with HIT.
• Consider induced hypertension to determine if symptoms can be ameliorated with augmented CBF. Patients with patent circle of
Willis by CTA or MRA may not benefit from induced hypertension and may be at greater risk of ICH.
• Consider neuroprotective therapies • Consider neurosurgical consultation in cerebellar infarction at risk for brainstem compression or hydrocephalus.
Phase 2

Subacute Medical Management
Communicate with PCP 
